Collaboration in more than 46 countries.

You are leaving the country website to access another site in the group. Regulatory constraints and medical practices vary from country to country. Consequently, the information provided on the site in which you enter may not be suitable for use in your country.

NORTH AMERICA

Canada

United States

LATIN AMERICA

Argentina

Brazil

Mexico

Perú

GLOBAL

CEVA Global

EMEA (REGIONAL)

Denmark

Egypt

France

Germany

Hungary

Italy

Netherlands

Poland

Portugal

Romania

South Africa

Spain

Sweden

Tunisia

Turkey

Ukraine

United Kingdom

ASIA PACIFIC

Asia Pacific (Regional)

China

India

Indonesia

Japan

Korea

Malaysia

Philippines

OBJECTIVES

Treatment of bovine respiratory disease (BRD) classically rely upon administration of a systemic antimicrobial targeting Gram-negative bacteria. Addition of a nonsteroidal anti-inflammatory drugs has proven to mitigate the inflammatory response and to rapidly improve the clinical condition of affected animals. Recently, a florfenicol and meloxicam combination was developed (Zeleris®, Ceva Santé Animale). To assess the efficacy of this combination in the field and to precise the benefits of combining meloxicam with florfenicol, a comparative field trial with a florfenicol-based product (Nuflor® 300, MSD) was carry out.

MATERIALS AND METHODS

329 young cattle were enrolled in a multicenter study performed in field conditions. Calves were included if they displayed a rectal temperature (RT) ≥ 40°C and a sum of clinical scores (CS) > 2. Calves were randomly allocated to one of the two groups and treated with Zeleris® or Nuflor®300 once subcutaneously according to manufacturer’s instructions. Calves were observed for 30 days and monitored for clinical signs (respiratory and behavioral scores) and rectal temperatures.

RESULTS

• 7 days after treatment, 93.9% of animals treated with Zeleris® were cured compared to 88.5% of animals treated with florfenicol alone (P=0.119).
• 6 hours post-treatment, calves receiving Zeleris® had a lower RT than calves treated with Nuflor®300 (39.4°C vs. 39.9°C, P<0.001). Moreover, 53% of the cattle that received Zeleris® had a normal RT 6 hours post-treatment while 83% of cattle treated with Nuflor®300 were still affected by fever (figure 1). Superiority of Zeleris® over Nuflor®300 was maintained for 48 hours after treatment for the control of fever (P=0.044).
• A higher number of calves showed an improvement in their CS as soon as 6h after treatment with Zeleris® compared to Nuflor®300 and up to day 3 (figure 2).

CONCLUSIONS

In this experimental study, the florfenicol and meloxicam combination (Zeleris®) was found to be highly effective for the treatment of BRD (cure rate = 100%). Calves treated with this new combination were moreover at lower risk for clinical relapse and presented a higher bodyweight gain compared to calves receiving the florfenicol and flunixin meglumine combination. These results are in line with the pharmacokinetic properties of florfenicol and meloxicam.

 

Don´t hesitate to read the rest of our publicatons and improve your knowledge about ruminats and their health!

Share this publication:

Publication file:

Download publication
This site is registered on wpml.org as a development site. Switch to a production site key to remove this banner.